Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Primaquine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 1/20 | 0.88 |
| ▸ | ADRB1 known ✓ | P08588 | 1/20 | 0.88 |
| ▸ | OPRM1 known ✓ | P35372 | 1/20 | 0.88 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.88 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 1.00 |
| ▸ | CASP1 | P29466 | 2/20 | 1.00 |
| ▸ | THRB | P10828 | 2/20 | 1.00 |
| ▸ | RAD52 | P43351 | 1/20 | 1.00 |
| ▸ | CASP7 | P55210 | 1/20 | 1.00 |
| ▸ | CASP6 | P55212 | 1/20 | 1.00 |
| ▸ | CASP8 | Q14790 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.88 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.88 |
| ▸ | TP53 | P04637 | 2/20 | 0.88 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.88 |
| ▸ | ESR1 | P03372 | 1/20 | 0.88 |
| ▸ | PGR | P06401 | 1/20 | 0.88 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.88 |
| ▸ | HTR1A | P08908 | 1/20 | 0.88 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.88 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Primaquine SCHEMBL29576219 | 1.00 | KDM4E (1.00) | KDM4ECASP1THRBRAD52CASP7 | |
| Primaquine SCHEMBL41096 | 1.00 | KDM4E (1.00) | KDM4ECASP1THRBRAD52CASP7 | |
| Primaquine SCHEMBL4333877 | 0.95 | KDM4E (0.91) | KDM4ECASP1THRBRAD52CASP7 | |
| Primaquine SCHEMBL29409423 | 0.94 | KDM4E (1.00) | KDM4ECASP1THRBRAD52CASP7 | |
| Primaquine SCHEMBL22208 | 0.94 | KDM4E (1.00) | KDM4ECASP1THRBRAD52CASP7 | |
| Primaquine SCHEMBL12599100 | 0.94 | KDM4E (1.00) | KDM4ECASP1THRBRAD52CASP7 | |
| Primaquine SCHEMBL22207 | 0.94 | KDM4E (1.00) | KDM4ECASP1THRBRAD52CASP7 | |
| Primaquine SCHEMBL4959404 | 0.93 | KDM4E (0.98) | KDM4ECASP1THRBRAD52CASP7 | |
| Primaquine SCHEMBL6333949 | 0.93 | KDM4E (0.98) | KDM4ECASP1THRBRAD52CASP7 | |
| Primaquine SCHEMBL979493 | 0.93 | KDM4E (0.98) | KDM4ECASP1THRBRAD52CASP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1808 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119060869-A | Outer membrane vesicles, preparation method and application thereof | 中国科学院分子植物科学卓越创新中心 | 2024-12-03 | — | — | CN | claimed |
| US-12097193-B2 | Methods for the administration of COMT inhibitors | BIAL—PORTELA & CA, S.A. (PT) | 2024-09-24 | — | — | US | claimed |
| US-20240282425-A1 | AUTHENTICATION METHODS AND SYSTEMS FOR DISPENSED PRESCRIPTIONS | LOW GORDON KEITH (US) | 2024-08-22 | — | — | US | claimed |
| US-20230346697-A1 | ANTIMICROBIAL AND ANTI-INFLAMMATORY COMPOSITIONS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2023-11-02 | — | — | US | claimed |
| US-20230201148-A1 | USES OF ORNITHINE PHENYLACETATE FOR TREATING HYPERAMMONEMIA | MALLINCKRODT LLC | 2023-06-29 | — | — | US | claimed |
| US-20230190969-A1 | METHOD, SYSTEM AND DEVICE TO REDUCE UNWANTED CELLS IN BIOLOGIC PRODUCTS | ROMCEVICH NICKOLAS (US) | 2023-06-22 | — | — | US | claimed |
| CN-114452289-B | Application of quinoline derivatives in preparation of medicines for preventing and/or treating gastrointestinal diseases | 兰州大学 | 2023-06-09 | — | — | CN | claimed |
| WO-2023078180-A1 | MINI-TABLET, AND PREPARATION METHOD THEREFOR AND FORMULATION THEREOF | 北京微智瑞医药科技有限公司 | 2023-05-11 | — | — | WO | claimed |
| CN-115916179-A | Use of ornithine phenylacetate for treating hyperammonemia | 欧塞拉治疗有限公司 | 2023-04-04 | — | — | CN | claimed |
| EP-4153162-A1 | USES OF ORNITHINE PHENYLACETATE FOR TREATING HYPERAMMONEMIA | Ocera Therapeutics, Inc. (US) | 2023-03-29 | — | — | EP | claimed |
| CN-1371689-A | New pharmaceutical usage of primaquine phosphate | LI JIMING (CN) | 2002-10-02 | — | — | CN | claimed |
| EP-1210116-A2 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF VIRAL INFECTIONS CONTAINING A CALCIUM CHANNEL BLOCKER AND A QUINOLINE | Immune Balance Technologies Limited Company (US) | 2002-06-05 | — | — | EP | claimed |
| US-20020035061-A1 | COMPOSITIONS AND METHODS FOR TREATING INFECTIONS USING CATIONIC PEPTIDES ALONE OR IN COMBINATION WITH ANTIBIOTICS | BIOWEST THERAPEUTICS INC. (CA) | 2002-03-21 | — | — | US | claimed |
| EP-1174439-A2 | Compositions and methods for treating infections using analogues of indolicidin | Micrologix Biotech, Inc. (CA) | 2002-01-23 | — | — | EP | claimed |
| WO-2001013907-A2 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF VIRAL INFECTIONS CONTAINING A CALCIUM CHANNEL BLOCKER AND A QUINOLINE | IMMUNE BALANCE TECHNOLOGIES LIMITED COMPANY (US) | 2001-03-01 | — | — | WO | claimed |
| JP-2001500477-A | — | — | 2001-01-16 | — | — | JP | claimed |
| CN-1237416-A | Compound piperaquine tablet | JIANQIAO MEDICINE SCIENCE & TE (CN) | 1999-12-08 | — | — | CN | claimed |
| EP-0925308-A2 | COMPOSITIONS AND METHODS FOR TREATING INFECTIONS USING ANALOGUES OF INDOLICIDIN | Micrologix Biotech, Inc. (CA) | 1999-06-30 | — | — | EP | claimed |
| WO-1998007745-A9 | COMPOSITIONS AND METHODS FOR TREATING INFECTIONS USING ANALOGUES OF INDOLICIDIN | — | 1998-04-23 | — | — | WO | claimed |
| WO-1998007745-A2 | COMPOSITIONS AND METHODS FOR TREATING INFECTIONS USING ANALOGUES OF INDOLICIDIN | MICROLOGIX BIOTECH, INC. (CA) | 1998-02-26 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12097193-B2 | Methods for the administration of COMT inhibitors | COMT, OPRK1, OPRM1 | ADRB2 394/4885ADRB1 269/4885OPRM1 3/4885 |
| US-20020035061-A1 | COMPOSITIONS AND METHODS FOR TREATING INFECTIONS USING CATIONIC PEPTIDES ALONE OR IN COMBINATION WITH ANTIBIOTICS | VIP, PEPD, PTMS | ADRB2 3799/4885ADRB1 3982/4885OPRM1 1565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.